Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: diffuse erythema as a positive predictor of complete remission

JAMA Dermatol. 2014 Jul;150(7):776-9. doi: 10.1001/jamadermatol.2013.10099.

Authors

Rei Watanabe¹, Jessica E Teague¹, David C Fisher², Thomas S Kupper³, Rachael A Clark¹

Affiliations

¹ Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
² Cutaneous Lymphoma Program, Dana-Farber Brigham and Women's Cancer Center, Boston, Massachusetts.
³ Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts2Cutaneous Lymphoma Program, Dana-Farber Brigham and Women's Cancer Center, Boston, Massachusetts.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Alemtuzumab
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents / therapeutic use*
Erythema / chemically induced
Erythema / pathology*
Humans
Induction Chemotherapy / methods
Leukemia / complications
Leukemia / drug therapy*
Lymphoma, T-Cell, Cutaneous / complications
Lymphoma, T-Cell, Cutaneous / drug therapy*
Skin Neoplasms / complications
Skin Neoplasms / drug therapy*
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Alemtuzumab

Grants and funding